Mortality and Severity in COVID-19 Patients on ACEIs & ARBs - A Meta-Regression Analysis

Romil Singh, MBBS¹; Sawai Singh Rathore, MBBS²; Hira Khan, MBBS³; Abhishek Bhurwal, MD⁴; Mack Sheraton MD, MHA⁵; Prithwish Ghosh, MBBS⁶; Sohini Anand, MBBS⁷; Janaki Makadia, MBBS⁸; FNU Ayesha, MBBS⁹; Kiran S. Mahapure, MS, MCH¹⁰; Ishita Mehra, MBBS¹¹; Aysun Tekin, MD¹; Rahul Kashyap, MBBS, MBA¹; Vikas Bansal, MBBS, MPH¹²

¹Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA

²Medical Student, Dr. Sampurnanand Medical College and Hospital, Jodhpur, Rajasthan, India

³Department of Internal Medicine, Islamic International Medical College, Rawalpindi, Pakistan

⁴Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ, USA

⁵Department of Emergency Medicine, Trinity West Medical Center, Steubenville, Ohio, USA

⁶Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

⁷Medical Graduate, Patliputra Medical College and Hospital, Dhanbad, Jharkhand, India

⁸Medical Graduate, GMERS Medical College and Hospital, Gotri, Vadodara, Gujrat, India

⁹Medical Graduate, Services Institute of Medical Sciences, Lahore, Pakistan

¹⁰Department of Plastic Surgery, KAHER J. N. Medical College, Belgaum, Karnataka, India

¹¹Departments of Internal Medicine, North Alabama Medical Center, Florence, AL, USA

¹²Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA

24 **Corresponding Author:**

25 Vikas Bansal, MBBS, MPH

26 Assistant Professor of Medicine,

27 Division of Pulmonary Medicine and Critical Care

28 Mayo Clinic, Rochester, MN-55905

29 Email: bansal.vikas@mayo.edu

30 Phone: 1-507-398-1595

31 **Word Count: Abstract - 261; Manuscript – 2399**

32 **Figures: 6**

33 **Tables: 2**

34 **Conflict of Interest Statement:** None of the authors have any conflict of interest to declare.

35 **Author Contribution:** *Authors RS and VB contributed equally in the defining the study
 36 outline and manuscript writing. Data review and collection done by AT, FA, HK, JM, KM, PG,
 37 RS, SA, and SSR. Statistical analysis was done by AB, MS, and VB. Study design and critical
 38 review done by IM and RK. RS, VB, AB, and MS are the guarantor of the paper, taking
 39 responsibility for the integrity of the work as a whole, from inception to published article.

40 **Keywords:** COVID-19, Angiotensin inhibitors, ACEI, ARB, Mortality, Severity, Meta-Analysis,
 41 Meta-Regression

42 **Abstract:**

43 **Purpose:** The primary objective of this review is to examine studies reporting association of
44 mortality in COVID-19 patients with whether they were on Angiotensin-converting-enzyme
45 inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). A secondary objective is to
46 similarly assess associations with higher severity of the disease in COVID-19 patients.

47 **Materials and Methods:** We searched multiple COVID-19 databases (WHO, CDC, LIT-
48 COVID) for randomized trials and longitudinal studies from all over the world reporting
49 mortality and severity published before January 18th, 2021. Meta-analyses were performed using
50 53 studies for mortality outcome and 43 for the severity outcome. Mantel-Haenszel odds ratios
51 were generated to describe overall effect size using random effect models. To account for
52 between study results variations, multivariate meta-Regression was performed with preselected
53 covariates using maximum likelihood method for both the mortality and severity models.

54 **Result:** Our findings showed that the use of ACEIs/ARBs did not significantly influence either
55 mortality (OR=1.16 95% CI 0.94 to 1.44, $p=0.15$, $I^2=93.2\%$) or severity (OR=1.18, 95% CI
56 0.94 to 1.48 $p=0.15$, $I^2=91.1\%$) in comparison to not being on ACEIs/ARBs in COVID-19
57 positive patients. Multivariate meta-regression for the mortality model demonstrated that 36% of
58 between study variations could be explained by differences in age, gender, and proportion of
59 heart diseases in the study samples. Multivariate meta-regression for the severity model
60 demonstrated that 8% of between study variations could be explained by differences in age,
61 proportion of diabetes, heart disease and study country in the study samples.

62 **Conclusion:** We found no association of mortality or severity in COVID-19 patients taking
63 ACEIs/ARBs.

Introduction: SARS-CoV-2 originated in Wuhan, China, in December 2019 and has spread to every major country in the world and was subsequently declared a pandemic on March 11, 2020¹. As of March 10th, 2021, there are 117,997,454 positive patients worldwide; and 2,619,379 of these patients were reported to be deceased because of SARS-CoV-2². The case fatality rate of SARS-CoV-2 in the U.S. is 1.05 per 1000 population as per COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University². However, the role of different medications and comorbidities has been elicited in recent articles.

The SARS-CoV-2 disease varies from mild to fulminant in reference to several risk variables contributing to a poor prognosis³⁻⁵. While the virus significantly impacts the respiratory tract, other metabolic systems have been involved in numerous case studies and systematic reviews⁶⁻¹⁴. Thorough awareness of the risks, pathogenesis, and predisposing factors together with the important aspects in the diagnosis is of paramount importance in order to direct decision-making for acute care and mitigate mortality of COVID-19¹⁵⁻¹⁹.

Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the receptor angiotensin-converting enzyme (ACE) 2 for entry into target cells, and it was reported that both Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the mRNA expression of cardiac ACE2 receptors²⁰. However, controversy about the novel use of Renin-angiotensin system (RAS) blockers has been raised amid this SARS-CoV-2 pandemic. The explanation behind this controversy arises from the very fact that it shares the target receptor site with ACEIs and ARBs, which can cause the upregulation of ACE2 receptors²¹. ACE2 is additionally the notable cellular surface receptor and a necessary entry point for SARS-CoV-2 into the target cell²². As cardiovascular diseases and their therapy affects ACE2 levels, it plays an integral part in consideration of infectivity and outcomes of SARS-CoV-2. It needs to be

imperatively determined whether treatment or disease-induced up-regulation of ACE2 impacts the trajectory of SARS-CoV-2²⁰. ACEIs/ARBs are often used to treat hypertension, which is the most common comorbidity associated with SARS-CoV-2²³. As there is no clinical evidence, major international cardiology societies recommend continuing the use of ACEIs and ARBs in SARS-CoV-2 patients²⁴.

Due to limited literature on the influence of ACE inhibitors and ARBs in COVID-19 patients, we systematically reviewed the relevant medical literature. We performed a meta-analysis and meta-regression to investigate the association of ACEIs and ARBs used in COVID-19 and its effect on the mortality rate and severity of COVID-19.

Methodology: We have presented this review according to the Preferred Systematic Reviews and Meta-Analysis Reporting Items guidelines for documenting analysis²⁵.

Search strategy: We searched WHO COVID-19 Global research database, Lit-COVID²⁶, CDC Database of COVID-19 Research including PubMed, Embase, Scopus, Science Web, and Cochrane Central Controlled Trials Registry. The MedRxiv and SSRN preprint servers were also scanned. The searches were performed from December 2019 and revised till January 18th, 2021. The search approach and design can be found in Figure-1. Studies from all around the world were included, there were no language barriers. In an attempt to discover further eligible studies, we manually searched the reference lists of the included studies and the relevant literature. We also scanned the clinicaltrials.gov registry for completed, as well as in-progress randomized controlled trials (RCTs).

Eligibility criteria: Criteria of eligibility: We included observational studies assessing the association between the use of the ACEI or ARB and at least one functional endpoint in COVID-

19 positive patients diagnosed by RT-PCR. Case reports, narrative reviews, commentaries, and abstracts were excluded. The cases included Covid-19 positive patients on ACEI or ARB and the controls included the remaining COVID-19 positive patients.

Study Selection: Three authors (RS, SSR, and HK) downloaded all articles from electronic search to EndNote X9²⁷, as well as duplicates were eliminated. Titles and abstracts were autonomously evaluated by authors (AT, FA, HK, JM, KM, PG, RS, SA, and SSR) to identify and assess key articles. Further, authors (FA, HK, JM, KM, PG, RS, SA, and SSR) independently reviewed the entire manuscript and registered justification for the exclusion. Any discrepancies were addressed by arbitration.

Outcome: All-cause mortality in the COVID-19 affected patient was the chief outcome, while severity of disease was the secondary outcome.

Data Extraction: The authors (FA, HK, JM, KM, PG, RS, SA, and SSR), using a standardized data extraction method, extracted information from each survey independently; any conflict was resolved by consensus. The following dataset points were extracted: First author name, cases on ACEI-ARB, total COVID positive patients, country of study, study design, hypertension proportion, diabetes proportion, heart disease proportion, eligibility criteria, Median age, gender (female sex proportion), comorbidities, use of ACEIs or ARBs and primary and secondary outcomes (mortality and severity). Unadjusted and adjusted impact measurements were also extracted where appropriate.

Statistical analysis: The meta-analysis specifically included longitudinal and cross-sectional studies comparing the effects of COVID-19 in subjects who were on ACEIs/ARBs at the time of infection with those who were not. Meta-analysis was performed first for studies reporting

mortality of patients in both groups, followed by that for studies reporting severity of disease assuming independence of results for studies that reported both. Due to anticipated heterogeneity, summary statistics were calculated using a random-effects model. This model accounts for variability between studies as well as within studies. In all cases, meta-analyses were performed using the Mantel-Haenszel method for dichotomous data to estimate pooled odds ratios (OR) and statistical heterogeneity was assessed using Q value and I^2 statistics. The meta-analysis and meta-regression was done with the Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA)²⁸. We included the region of study in meta-regression model to find out whether Asian studies, which were dated earlier than studies from the rest of the world, contributed disproportionately to the significance of results. This helped rule out location and pipeline biases.

To explore differences between studies that might be expected to influence the effect size, we performed random effects (maximum likelihood method) univariate and multivariate meta-regression analyses. The potential sources of variability defined were median age of study sample, proportion of subjects of female sex, proportion of diabetics and proportion with heart diseases. Covariates were selected for further modeling if they significantly ($P < 0.05$) modified the association between mortality or severity in the COVID19 infected and treatment with ACEIs/ARBs. Two models were created, one for mortality and the other for severity of disease as outcomes. Subsequently, preselected covariates were included in a manual backward and stepwise multiple meta-regression analysis with $P = 0.05$ as a cutoff point for removal. $P < 0.05$ ($P < 0.10$ for heterogeneity) was considered statistically significant. All meta-analysis and meta-regression tests were 2-tailed.

Results:

The initial library search identified potentially relevant citations from WHO Global Research Database, CDC COVID-19 Research Articles Downloadable Database, and LitCovid PubMed database comprised of 393,597 articles. Subsequently, 393,285 articles were removed because of unclear evidence and non-relevance to the objective of the manuscript. Out of the remaining 312 articles, a total of 244 articles consisting of case reports, abstracts, letter to editor, and narrative reviews were excluded. Thus, 68 studies²⁹⁻⁹⁶ were included in their entirety as shown in Table 1. The PRISMA flow chart is shown in Figure 1.

Study characteristics of included studies: A total of fifty three studies²⁹⁻⁸¹ were included for meta-analysis for the primary outcome i.e. mortality. In total, these consisted of 112,468 subjects with 16,363 mortality events. Median age for all studies was 64.9 (60.9-67.2) with average 47.3% females (Table 1). Of the comorbidities considered, 25.4% were diabetics, 16.6% had heart diseases overall. Similarly, a total of forty three studies^{29,31,33,36-38,41,43,45-47,49,53,55-57,59-61,64-66,69,73,74,76,77,79,82-96} were included for meta-analysis for the secondary outcome i.e. severity of disease. These had a combined sample size of 37,914 with 6,985 patients reaching the endpoint of high disease severity. The median age was 65.2 (60.8-68.7) and 46.2% were females, 25.6% were diabetics, 17.1% had heart diseases overall in this cohort (Table 1).

Meta-analysis for mortality outcome: Meta-analysis findings showed that being on ACEIs/ARBs did not have an association with mortality from COVID 19 infections compared to not being on ACEIs/ARBs (OR=1.17, 95% CI 0.94 to 1.45, p= 0.15). Heterogeneity was very high with $I^2 = 93.2\%$ (Figure 2).

Meta-analysis for severity outcome: Findings from the meta-analysis showed that being on ACEI/ARBs did not have an association with severity from COVID 19 infections compared to

not being on ACEIs/ARBs (OR=1.18, 95% CI 0.94 to 1.48, $p=0.15$). Heterogeneity was very high with $I^2=91.1\%$ (Figure 3).

Multivariate meta-regression model for mortality outcome: Multivariate meta-regression performed to explain variations in association between mortality and being on ACEIs/ARBs revealed; age, female gender, proportion of heart diseases in included studies covariates to be significant together and explained $R^2=36\%$ of the between study heterogeneity in mortality. Figure 4 shows the resulting equation and individual covariate effect graphs.

Multivariate meta-regression model for severity outcome: Multivariate meta-regression performed to explain variations in association between severity and being on ACEIs/ARBs revealed age, proportion with diabetes, heart disease and country of studies covariates to be significant together. These covariates together explained $R^2=8\%$ of the study heterogeneity in severity. Figure 5 shows the resulting equation and individual covariate effect graphs.

Risk of bias assessment- The Newcastle-Ottawa (NOS) scale⁹⁷ was used for measuring the risk of bias in cohort and case-control studies (Table 2A & 2B). The following classes were rated per study: low bias risk (9 points), moderate bias risk (5-7 points), and high bias risk (0-4 items). For a cross-sectional study, we used the modified version of NOS, assigning the study in the following groups: Low risk of bias (8-10), moderate risk (5-7), high risk of bias (0-4). Three reviewers (RS, SSR, and PG) evaluated the likelihood of bias independently, and any conflict was resolved by consensus.

Publication Bias:

Visual inspection of the standard error plots for the mortality analysis (Figure 6A) suggests symmetry without an underrepresentation of studies of any precision but indicated underrepresentation of studies with smaller effect sizes. Classic fail-safe N analysis computed taking alpha at 0.05 put the number of missing studies at 5. Corroborating inspection findings, in Egger's regression test the null hypothesis of no small study effects was not rejected at $P < 0.05$ (estimated bias coefficient = -0.28 ± 0.76 SE).

Similarly, visual inspection of the standard error plots for the severity analysis also (Figure 6B) suggest symmetry without an underrepresentation of studies of any precision but indicated underrepresentation of studies with smaller effect sizes. Classic fail-safe N analysis computed taking alpha at 0.05 put the number of missing studies at 8. However, in Egger's regression test the null hypothesis of no small study effects was rejected at $P < 0.05$ (estimated bias coefficient = -1.14 ± 0.81 SE).

Discussion:

Based on our meta-analysis consisting of cross-sectional, case-control, and cohort studies, the use of ACEIs and ARBs was neither associated with increased all-cause mortality nor with increased severity of disease progression in COVID-19 patients. Multivariate meta-regression for the mortality model demonstrated that 36% of study variations could be explained by differences in age, female gender, proportion of heart diseases in the study samples. Multivariate meta-regression for the severity model demonstrated that 8% of study variations could be explained by

differences in age, proportion of diabetes, heart diseases and country of studies in the study samples. This finding is valuable as association between ACEIs and ARBs use and outcome in COVID-19 patients has been inconclusive so far. To our knowledge, this is the first meta-regression, and the largest meta-analysis to evaluate the role of ACEIs/ARBs as an antihypertensive regimen in hospitalized patients with COVID-19.

The effect of ACEIs/ARBs use on COVID-19 patients has been a controversial topic since the beginning of this pandemic, and some studies even have interposed a risk of taking ACEIs/ARBs using data from previous coronavirus outbreaks and preclinical studies⁹⁸. Previously published systematic reviews, suggested a lower mortality (25-43%) in patients with hypertension hospitalized for COVID19⁹⁹⁻¹⁰¹. Furthermore, a large-scale retrospective study demonstrated that in-hospital use of ACEIs/ARBs was associated with a lower risk of 28-day death among hospitalized patients with COVID-19 and coexisting hypertension (adjusted HR 0.32, 95% CI 0.15 to 0.66)⁷⁸. These data suggested that patients with hypertension might obtain benefits from taking ACEIs/ARBs compared with the non-ACEIs/ARBs in the setting of COVID-19 and support the hypothesis that a drug that diminishes angiotensin-2 activity, such as ACEIs and/or ARBs, can reduce the deadliness of inflammation associated injury in COVID-19. Our result trends in contraindicating the above study results but did not reach statistical significance. Our meta-analysis suggests that the use of ACEIs/ARBs neither increase nor decrease mortality in COVID-19 patients (figure 2). In addition to what is reported in published studies, our systematic review added the most recent studies, and had the largest sample size (53 studies, 112,468 patients).

The main strength of our analysis is the large sample size along with a robust and comprehensive search. The large sample size enables the precision and reliability of risk estimates. Additionally, further meta-regression was performed to adjust for confounding factors. However, despite all the strengths, there are still certain limitations. The major limitation of the meta-regression is the presence of unknown confounders. Multiple previous studies have reported that gender, age, smoking history, and presence of diabetes influence COVID-19 results. Even though these confounders are reported in most of the included studies, further studies focusing on the adjustment of confounders are necessary. We included studies from the medRxiv.org databases and other preprint database which did not go through peer review at that time. We considered this as a limitation, as peer reviewers could catch more deficiencies in reporting methods and other details. However, it was anticipated that majority of these studies would be peer-reviewed. Third, the use of ACE/ARB has been via medical record review which could be less reliable. Finally, the definition of COVID-19 severity and outcomes were not uniform among the included studies.

In conclusion, meta-regression analysis suggest that the use of ACEIs/ARBs in patients with COVID-19 is not associated with increased mortality or increased severity. However, multivariate meta-regression model for mortality indicated that 36% study variation could be due to differences in age, female gender, proportion of heart diseases in the study samples. Similarly, multivariate meta-regression for the severity model exhibited that 8% of study variations could be explained by differences in age, proportion of diabetes, heart disease and country of studies in the study samples. Larger observational studies¹⁰²⁻¹⁰⁵ and clinical trials are warranted to confirm these findings. Providers should continue to manage patient hypertension as per current treatment guidelines^{106,107} and clinical judgement.

References:

1. Shah A, Kashyap R, Tosh P, Sampathkumar P, O'Horo JC. Guide to Understanding the 2019 Novel Coronavirus. *Mayo Clin Proc.* 2020;95(4):646-652.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020;20(5):533-534.
3. Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. *Critical Care Medicine.* 9000;Online First.
4. Bansal V, Singh R, Bhurwal A, Rathore S, Kashyap R. 117: Obesity Is a Risk Factor for Increased COVID-19 Severity: A Systemic Review and Meta-Regression. *Critical Care Medicine.* 2021;49(1):43.
5. Kirkup C, Pawlowski C, Puranik A, et al. Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry. *J Med Virol.* 2021.
6. Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with Covid-19 disease: a systematic review of published Case reports and Case series. *Authorea.* 2021.
7. Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of COVID-19. *Cureus.* 2020;12(5).
8. Khan H, Sabzposh H, Deshpande S, Kashyap R. Pregnancy during COVID-19 pandemic– Maternal and neonatal outcomes: A concise review. *International Journal of Academic Medicine.* 2020;6(4):287.
9. Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental Health of Children and Adolescents. *Cureus.* 2020;12(8).
10. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review. *Psychiatry research.* 2020;292:113360.
11. Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac Complications in Coronavirus Disease 2019. *Cureus.* 2020;12(5).
12. Bhalala U, Gist K, Tripathi S, et al. 145: Pediatric COVID-19: A Report From Viral Infection and Respiratory Illness Universal Study (VIRUS). *Critical Care Medicine.* 2021;49(1):58.
13. Tripathi S, Gist K, Chiotos K, et al. 61: Risk Factors for Severe COVID-19 Illness in Children: Analysis of the VIRUS: COVID-19 Registry. *Critical Care Medicine.* 2021;49(1):32.
14. Menon T, Sharma R, Earthineni G, et al. Association of Gastrointestinal System With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis. *Cureus.* 2021;13(2).
15. Mehra I, Mahapure K, Armaly P, et al. 146: Controversial Role of Corticosteroids on Mortality in COVID-19: Systematic Review and Meta-Analysis. *Critical Care Medicine.* 2021;49(1):58.
16. R Singh LS, I Mehra, R Kashyap, S Surani. Novel and Controversial Therapies in COVID-19. *The Open Respiratory Medicine Journal.* 2020;14.
17. Bansal V, Mahapure K, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-analysis. *Frontiers in Medicine.* 2020;7:1124.

18. Jain R, Javeri Y, Nasa P, et al. Consensus Statement for Pharmacological Management of Coronavirus Disease 2019 (COVID-19): A Pragmatic Approach. *Asploro Journal of Biomedical and Clinical Case Reports*. 2020;3(3):241.
19. Kirkup C, Pawlowski C, Puranik A, et al. Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry. *medRxiv*. 2020.
20. Sommerstein R, Kochen MM, Messerli FH, Grani C. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? *J Am Heart Assoc*. 2020;9(7):e016509.
21. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020;579(7798):265-269.
22. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. *Int J Pept*. 2012;2012:256294.
23. Kanwal A, Agarwala A, Martin LW. COVID-19 and Hypertension: What We Know and Don't Know. *American College of Cardiology*. 2020;6.
24. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. *JAMA Cardiol*. 2020;5(7):745-747.
25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
26. Chen Q, Allot A, Lu Z. LitCovid: an open database of COVID-19 literature. *Nucleic Acids Res*. 2021;49(D1):D1534-D1540.
27. Hupe M. EndNote X9. *Journal of Electronic Resources in Medical Libraries*. 2019;16(3-4):117-119.
28. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. <https://www.meta-analysis.com/index.php?cart=BBFA4702757>. Published 2013. Updated 03/11/2021. Accessed 03/11/2021.
29. Bae DJ, Tehrani DM, Rabadia SV, et al. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19. *Am J Cardiol*. 2020;132:150-157.
30. Baker KF, Hanrath AT, Schim van der Loeff I, et al. COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis. *Med Sci (Basel)*. 2021;9(1):2020.2005.2014.20100834.
31. Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. *Kidney Int*. 2020;97(6):1076-1082.
32. Bauer AZ, Gore R, Sama SR, et al. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. *The Journal of Clinical Hypertension*. 2021;23(1):21-27.
33. Bean D, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute Hospital Trust. *medRxiv*. 2020:2020.2004.2007.20056788.
34. Benelli G, Buscarini E, Canetta C, et al. SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. *medRxiv*. 2020:2020.2004.2014.20053090.

35. Braude P, Carter B, Short R, et al. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. *Int J Cardiol Heart Vasc.* 2020;31:100660.
36. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia.* 2020;63(8):1500-1515.
37. Cetinkal G, Balaban Kocas B, Ser OS, et al. The Association between Chronic Use of Renin–Angiotensin–Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension. *Med Bull Sisli Etfal Hosp.* 2020;54(4):399-404.
38. Chaudhri I, Koraishy FM, Bolotova O, et al. Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection. *Kidney360.* 2020;1(8):801-809.
39. Chen M, Fan Y, Wu X, et al. Clinical Characteristics And Risk Factors For Fatal Outcome in Patients With 2019-Coronavirus Infected Disease (COVID-19) in Wuhan, China. *SSRN Electronic Journal.* 2020.
40. Chen Y, Yang D, Cheng B, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. *Diabetes Care.* 2020;43(7):1399-1407.
41. Choi HK, Koo H-J, Seok H, et al. ARB/ACEI use and severe COVID-19: a nationwide case-control study. *medRxiv.* 2020:2020.2006.2012.20129916.
42. Conversano A, Melillo F, Napolano A, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia. *Hypertension.* 2020;76(2):e10-e12.
43. Covino M, De Matteis G, Burzo ML, et al. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. *Internal Medicine Journal.* 2020;50(12):1483-1491.
44. Desai A, Voza G, Paiardi S, et al. The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. *International Journal of Cardiology.* 2021;324:249-254.
45. Felice C, Nardin C, Di Tanna GL, et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives. *Am J Hypertens.* 2020.
46. Fosbol EL, Butt JH, Ostergaard L, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. *JAMA.* 2020;324(2):168-177.
47. Genet B, Vidal J-S, Cohen A, et al. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients. *Journal of the American Medical Directors Association.* 2020;21(11):1539-1545.
48. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020;5(7):811-818.
49. Hakeam HA, Alsemari M, Al Duhailib Z, et al. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter,

- Prospective Study. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2020;1074248420976279.
50. Huang Z, Cao J, Yao Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann Transl Med*. 2020;8(7):430.
51. Ip A, Parikh K, Parrillo JE, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *medRxiv*. 2020:2020.2004.2024.20077388.
52. Jung S-Y, Choi JC, You S-H, Kim W-Y. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study. *Clinical Infectious Diseases*. 2020.
53. Kim JH, Baek Y-H, Lee H, Choe YJ, Shin HJ, Shin J-Y. Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study. *medRxiv*. 2020:2020.2007.2029.20164822.
54. Kim L, Garg S, O'Halloran A, et al. Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *medRxiv*. 2020:2020.2005.2018.20103390.
55. Lafaurie M, Martin-Blondel G, Delobel P, Charpentier S, Sommet A, Moulis G. Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. *Fundamental & Clinical Pharmacology*. 2021;35(1):194-203.
56. Lahens A, Mullaert J, Gressens S, et al. Association between renin–angiotensin–aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. *Journal of Hypertension*. 2021;39(2):367-375.
57. Lam KW, Chow KW, Vo J, et al. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. *The Journal of Infectious Diseases*. 2020;222(8):1256-1264.
58. Lee H-Y, Ahn J, Kang CK, et al. Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome. *SSRN Electronic Journal*. 2020.
59. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol*. 2020;5(7):825-830.
60. Lim J-H, Cho J-H, Jeon Y, et al. Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. *Scientific Reports*. 2020;10(1):20250.
61. Liu X, Liu Y, Chen K, et al. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study. *Journal of Medical Virology*. 2021;93(2):854-862.

62. Lopez-Otero D, Lopez-Pais J, Cacho-Antonio CE, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. *CARDIOVID registry. Rev Esp Cardiol (Engl Ed)*. 2020.
63. Mehta N, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(9):1020-1026.
64. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect*. 2020;9(1):757-760.
65. Oussalah A, Gleye S, Clerc Urmes I, et al. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. *Clinical Infectious Diseases*. 2020;71(9):2447-2456.
66. Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2020;48(6):450-455.
67. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. *medRxiv*. 2020:2020.2004.2009.20059964.
68. Rezel-Potts E, Douiri A, Chowienczyk PJ, Gulliford MC. Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom. *medRxiv*. 2020:2020.2009.2025.20201731.
69. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052-2059.
70. Rodilla E, Saura A, Jiménez I, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. *Journal of Clinical Medicine*. 2020;9(10).
71. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. *JAMA Network Open*. 2020;3(12):e2029058-e2029058.
72. Rossi GP, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. *PLoS One*. 2020;15(8):e0238281.
73. Soleimani A, Kazemian S, Karbalai Saleh S, et al. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. *American Journal of Hypertension*. 2020;33(12):1102-1111.
74. Tan N-D, Qiu Y, Xing X-B, Ghosh S, Chen M-H, Mao R. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. *Gastroenterology*. 2020;159(3):1170-1172.e1171.
75. Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. *Am J Respir Crit Care Med*. 2020;201(11):1430-1434.

76. Yang G, Tan Z, Zhou L, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. *medRxiv*. 2020:2020.2003.2031.20038935.
77. Zeng Z, Sha T, Zhang Y, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. *medRxiv*. 2020:2020.2004.2006.20054825.
78. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circulation Research*. 2020;126(12):1671-1681.
79. Zhong Y, Zhao L, Wu G, et al. Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. *Journal of International Medical Research*. 2020;48(12):0300060520979151.
80. Zhou F, Liu Y-M, Xie J, et al. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. *Hypertension*. 2020;76(2):e15-e17.
81. Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. *Clinical and Experimental Hypertension*. 2020;42(7):656-660.
82. Ashraf MA, Shokouhi N, Shirali E, et al. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. *medRxiv*. 2020:2020.2004.2020.20072421.
83. Bravi F, Flacco ME, Carradori T, et al. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. *PLoS One*. 2020;15(6):e0235248.
84. De Spiegeleer A, Bronselaer A, Teo JT, et al. The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents. *medRxiv*. 2020:2020.2005.2011.20096347.
85. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. *Am J Respir Crit Care Med*. 2020;201(11):1380-1388.
86. Feng Z, Li J, Yao S, et al. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. *medRxiv*. 2020:2020.2004.2008.20057539.
87. Golpe R, Pérez-de-Llano LA, Dacal D, Guerrero-Sande H, Pombo-Vide B, Ventura-Valcárcel P. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. *Medicina Clínica*. 2020.
88. Güner R, Hasanoğlu İ, Kayaaslan B, et al. COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic's first month in Turkey. *Turk J Med Sci*. 2020.
89. Jurado A, Martin MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. *Immun Ageing*. 2020;17:22.

90. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. *medRxiv*. 2020:2020.2003.2020.20039586.
91. Mancia G, Rea F, Ludergrani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. *New England Journal of Medicine*. 2020;382(25):2431-2440.
92. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. *New England Journal of Medicine*. 2020;382(25):2441-2448.
93. Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. *medRxiv*. 2020:2020.2005.2020.20108555.
94. Yan HD, Valdes AM, Vijay A, et al. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. *Clin Pharmacol Ther*. 2020;108(6):1185-1194.
95. Anzola GP, Bartolaminelli C, Gregorini GA, et al. Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort. *Intern Emerg Med*. 2020;15(8):1477-1484.
96. Huh K, Ji W, Kang M, et al. Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. *Int J Infect Dis*. 2020;104:7-14.
97. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Published 2009. Updated 03/11/2021. Accessed 03/11/2021.
98. Ferrario CM, Ahmad S, Groban L. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. *Nat Rev Cardiol*. 2020;17(6):378.
99. Guo X, Zhu Y, Hong Y. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. *Hypertension*. 2020;76(2):e13-e14.
100. Ssentongo AE, Ssentongo P, Heilbrunn ES, et al. Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. *Open Heart*. 2020;7(2):e001353.
101. Lee MMY, Docherty KF, Sattar N, et al. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2020.
102. Walkey AJ, Kumar VK, Harhay MO, et al. The Viral Infection and Respiratory Illness Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical Illness. *Crit Care Explor*. 2020;2(4):e0113.
103. Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. *Crit Care Med*. 2021.
104. Turek JR, Bansal V, Tekin A, et al. Rapid Project Management in a Time of COVID-19 Crisis: Lessons learned from a Global VIRUS: COVID-19 Registry. *JMIR Preprints*. 2021.

105. Walkey AJ, Sheldrick RC, Kashyap R, et al. Guiding Principles for the Conduct of
Observational Critical Care Research for Coronavirus Disease 2019 Pandemics and
Beyond: The Society of Critical Care Medicine Discovery Viral Infection and Respiratory
Illness Universal Study Registry. *Crit Care Med*. 2020;48(11):e1038-e1044.
106. International Society of Hypertension. A statement from the International Society of
Hypertension on COVID-19. [https://ish-world.com/news/a/A-statement-from-the-
International-Society-of-Hypertension-on-COVID-19/](https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/). Published 2020. Updated
03/11/2021. Accessed 03/11/2021.
107. Statement from the American Heart Association, Heart Failure Society of America,
American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19
should continue treatment, unless otherwise advised by their physician. *Heart Fail Soc
Am*. 2020.

575 **Figure 1: PRISMA flow diagram**

576 **Figure 2: Forest plot for association of ACE/ARBs on mortality in COVID19 patients**

577 **Figure 3: Forest plot for association of ACE/ARBs on severity in COVID19 patients**

578

COVID Severity Benefit from ACE/ARB

579 **Figure 4: Meta-regression results for covariates significantly influencing mortality ($R^2=36$)**

580 **Figure 5: Meta-regression results for covariates significantly influencing severity ($R^2=8\%$)**

581 **Figure 6: Funnel plots for publication bias of Mortality (A) and Severity (B) models:**

582 **(A) Funnel Plot for publication bias of Mortality**

583 **(B) Funnel Plot for publication bias of Severity**

584

585

Table 1: Study characteristics

First Author	Publication Status	Type of study	Outcome data	Country of Study	Median Age	Female Sex Proportion	Diabetes Proportion	Heart Diseases Proportion	Hypertension Proportion (in percentage)	High Severity (Case)	High Severity Sample size (case)	High Severity (Control)	High Severity Sample size (Control)	Mortality (Case)	Sample size (case)	Mortality (Control)	Sample size (control)
Alexandre et al.	peer-reviewed	Retrospective Cohort study	All-cause Mortality & Severity	UK	61	39.76	28.24	17.57	48.7	17	117	12	230	17	117	12	230
Anzola et al.	peer-reviewed	prospective study	Severity	Italy	65	39	14	21	51	35	140	16	291	N/A	N/A	N/A	N/A
Ashraf et al.	pre-print	Cross Sectional Cohort	Severity	Iran	58	35.4	26	19	26	4	19	11	81	N/A	N/A	N/A	N/A
Bae et al.	peer-reviewed	Cohort	All-cause Mortality & Severity	USA	52	51.2	26.2	8.9	25.4	20	78	54	512	1	78	5	512
Baker et al.	pre-print	Cohort	All-cause Mortality	UK	75	46	26.6	20.6	42.1	N/A	N/A	N/A	N/A	17	78	63	233
Banerjee et al.	peer-reviewed	Cohort	All-cause Mortality & Severity	UK	61.5	42.8	43.8	N/A	100	1	1	1	6	1	1	0	6
Bauer et al.	peer-reviewed	case-control study	All-cause Mortality	USA	54.7	63	17	7	36	N/A	N/A	N/A	N/A	77	230	198	1219
Bean et al.	peer-reviewed	Case-Control	All-cause Mortality & Severity	UK	69.235	42.8	34.8	13.3	100	127	399	288	801	106	399	182	801
Benelli et al.	pre-print	Cohort	All-cause Mortality	Italy	66.8	33.4	16.3	22.6	46.95	N/A	N/A	N/A	N/A	25	110	47	301
Braude et al.	peer-reviewed	multicenter observational study	All-cause Mortality	UK+ Italy	74	40.9	27.1	21.8	51.5	N/A	N/A	N/A	N/A	106	392	257	979
Bravi et al.	peer-reviewed	Case-Control	Severity	Italy	58	52.3	12.1	16.1	33.9	267	450	69	93	N/A	N/A	N/A	N/A
Cariou et al.	peer-reviewed	Cohort	All-cause Mortality & Severity	France	69.8	35.1	88.5	11.6	77.2	232	737	150	580	92	737	48	580
Cetinkal et al.	peer-reviewed	Retrospective single center study	All-cause Mortality & Severity	Turkey	68.7	49.57	40.4	51	100	45	201	27	148	29	201	20	148
Chaudri et al.	peer-reviewed	Single center Cohort study	All-cause Mortality & Severity	USA	62	34	24.6	28.6	44.3	59	80	22	220	5	80	25	220
Chen Ming et al.	pre-print	Case control	All-cause Mortality	China	28.85	50.4	11.3	16.2	33.33	N/A	N/A	N/A	N/A	3	11	28	112
Chen Yuchen et al.	peer-reviewed	Cohort	All-cause Mortality	China	67.25	33	100	N/A	100	N/A	N/A	N/A	N/A	4	32	10	39

Choi et al.	pre-print	Case Control	All-cause Mortality & Severity	South Korea	66.5	57.2	44.9	N/A	100	34	892	55	625	42	892	69	625
Conversano et al.	peer-reviewed	Cohort	All-cause Mortality	Italy	65	31.4	14.6	4.7	50.26	N/A	N/A	N/A	N/A	48	69	101	122
De Spiegele er et al.	peer-reviewed	Cohort	Severity	Europe	85.9	67	18.1	N/A	25.3	6	30	31	124	N/A	N/A	N/A	N/A
Covino et al.	peer-reviewed	Retrospective study	All-cause Mortality & Severity	Austral ia	74	34.3	13.2	42.1	100	38	51	82	115	58	111	22	55
Desai et al.	peer-reviewed	retrospective study	All-cause Mortality	Italy	64.8	33.9	20	27.1	43.1	N/A	N/A	N/A	N/A	49	154	72	421
Felice et al.	peer-reviewed	Cohort	All-cause Mortality & Severity	Italy	72	35.4	25.5	18	100	21	82	25	51	15	82	18	51
Zhou feng et al.	peer-reviewed	Cohort	All-cause Mortality	China	66	49.9	N/A	N/A	100	N/A	N/A	N/A	N/A	70	906	272	1812
Fosbol et al.	peer-reviewed	Cohort	All-cause Mortality & Severity	Denma rk	62	52	9	8.5	18.8	203	895	373	3585	181	895	297	3585
Golpe et al.	peer-reviewed	Cohort	Severity	Spain	70.4	54.1	9.8	N/A	29.1	48	69	73	88	N/A	N/A	N/A	N/A
Guner et al.	peer-reviewed	Cohort	Severity	Turkey	50.6	40.5	13.5	23.6	23.4	21	65	29	167	N/A	N/A	N/A	N/A
Genet et al.	peer-reviewed	Retrospective Observational study	All-cause Mortality & Severity	USA	86.3	36.19	10.45	12.6	33.5	14	63	52	138	14	63	52	138
Guo et al.	peer-reviewed	Cross Sectional	All-cause Mortality	China	58	51.3	15	15.5	32.62	N/A	N/A	N/A	N/A	7	19	36	168
Hakeam et al.	peer-reviewed	Multicenter prospective Cohort	All-cause Mortality & Severity	Saudi Arabia	60.8	40.5	63.3	32.2	93.7	69	245	33	93	15	69	7	33
Huh et al.	peer-reviewed	retrospective cohort study	Severity	Korea	47.1	59.54	16.06	7.83	21.47	248	877	630	6464	N/A	N/A	N/A	N/A
Huang et al.	peer-reviewed	Cohort	All-cause Mortality	China	60.185	55	8	2	100	N/A	N/A	N/A	N/A	0	20	3	30
Kim Ju Hwan et al.	peer-reviewed	Retrospective Cohort study	All-cause Mortality & Severity	South Korea	62.8	49.79	62.69	53.89	22.6	23	628	28	608	23	628	28	608
Ip et al.	pre-print	Cross Sectional	All-cause Mortality	USA	N/A	N/A	N/A	N/A	52.5	N/A	N/A	N/A	N/A	137	460	262	669
Jurado et al.	pre-print	Cross Sectional	Severity	Spain	63.2	40.6	23.8	N/A	52.4	56	92	135	198	N/A	N/A	N/A	N/A
Jung et al.	peer-reviewed	Cohort	All-cause Mortality	South Korea	44.6	56	17	5	22.34	N/A	N/A	N/A	N/A	33	377	51	1577
Kim Lindsay et al.	peer-reviewed	Cohort	All-cause Mortality	USA	62	46.8	32.9	34.6	57.32	N/A	N/A	N/A	N/A	105	573	530	3214
Lafaurie et al.	peer-reviewed	Cohort study	All-cause Mortality & Severity	UK	74	77.56	12.92	12.9	38.78	36	73	14	36	9	73	6	36
Lee et al.	pre-print	Cohort	All-cause Mortality	South Korea	44.36	77.56	17	6.7	19	N/A	N/A	N/A	N/A	50	977	62	7289
Li et al.	peer-reviewed	Cross Sectional	All-cause Mortality & Severity	China	66	47.8	35	35.07	30.73	57	115	116	247	21	115	56	247
Liu et al.	pre-print	Cross Sectional	Severity	China	65.2	44.9	N/A	N/A	15.26	7	22	31	56	N/A	N/A	N/A	N/A

Mancia et al.	peer-reviewed	Cross Sectional	Severity	Italy	68	36.7	N/A	30.1	58	364	2896	253	3376	N/A	N/A	N/A	N/A
Lim et al.	peer-reviewed	Retrospective Cohort study	All-cause Mortality & Severity	South Korea	67	46.15	25.38	10	40	14	30	22	100	14	30	22	100
Mehta et al.	peer-reviewed	Cohort	All-cause Mortality	USA	58.5	49.9	41.1	19.9	11.6	N/A	N/A	N/A	N/A	8	211	34	1494
Meng et al.	peer-reviewed	Cross Sectional	All-cause Mortality & Severity	China	64.5	42.8	30.95	N/A	10	4	17	12	25	0	17	1	25
Lopez-Otero et al.	peer-reviewed	Cohort	All-cause Mortality	Spain	64.05	56	13	21.2	100	N/A	N/A	N/A	N/A	11	211	27	755
Oussalah et al.	peer-reviewed	retrospective longitudinal cohort analysis	All-cause Mortality & Severity	France	65	39	29	29	50	20	44	34	105	10	43	9	104
Peng et al.	peer-reviewed	Cross Sectional	All-cause Mortality & Severity	China	31	52.68	26	66.3	82.14	3	22	13	90	4	22	13	90
Rezel-Potts et al.	peer-reviewed	case control study with additional cohort analysis	All-cause Mortality	UK	62	60	13	14	26.8	N/A	N/A	N/A	N/A	254	2712	667	14154
Reynolds et al.	peer-reviewed	Cross Sectional	Severity	USA	32	58.5	39.7	16.1	34.59	587	2401	608	2393	N/A	N/A	N/A	N/A
Rhee et al.	pre-print	Cohort	Severity	South Korea	62.375	46.5	N/A	18.5	68.02	13	327	21	505	N/A	N/A	N/A	N/A
Rentsch et al.	pre-print	Cohort	All-cause Mortality	USA	66.1	4.6	44.4	27.9	71.96	N/A	N/A	N/A	N/A	11	255	6	324
Richardson et al.	peer-reviewed	Cross Sectional	All-cause Mortality & Severity	USA	63	39.7	59.8	33.8	53.08	87	413	141	953	130	413	254	953
Rodilla et al.	peer-reviewed	Cross-sectional, observational, retrospective multicenter study,	All-cause Mortality	Spain	67.5	42.6	19.1	4	50.9	N/A	N/A	N/A	N/A	1180	4238	1452	7988
Rosenthal et al.	peer-reviewed	retrospective cohort study	All-cause Mortality	USA	57	50.1	27.9	22.09	46.7	N/A	N/A	N/A	N/A	345	3162	7010	34545
Rossi et al.	pre-print	Cohort	All-cause Mortality	Italy	31.6	49.9	12	5.8	16.2	N/A	N/A	N/A	N/A	108	818	109	1835
Soleimani et al.	peer-reviewed	Retrospective Observational study	All-cause Mortality & Severity	USA	66.4	16.5	0.18	13.99	39.93	91	122	91	132	33	122	35	132
Tan et al.	peer-reviewed	Case Control	All-cause Mortality & Severity	China	67.25	49	28	18	100	27	31	60	69	0	31	11	69
W Lam et al.	peer-reviewed	Retrospective single center study	All-cause Mortality & Severity	USA	70.5	9.89	8.96	8.24	31.37	65	335	55	279	58	335	62	279
Wang et al.	peer-reviewed	Cross Sectional	All-cause Mortality	China	64	48	18.6	11.6	41.86	N/A	N/A	N/A	N/A	30	62	103	282
Zhou Xian et al.	peer-reviewed	Case-Control	All-cause Mortality	China	57.7	45.5	10	9.1	32.7	N/A	N/A	N/A	N/A	2	15	5	21
Yan et al.	pre-print	Cohort	Severity	China	48.75	48.9	10	2.62	22.46	52	256	76	354	N/A	N/A	N/A	N/A
Liu Xiulan et al.	peer-reviewed	retrospective single-center case series	All-cause Mortality & Severity	China	65.39	53.5	22	16	100	31	74	38	83	5	74	1	83

Yang et al.	pre-print	Cohort	All-cause Mortality & Severity	China	66.5	50.8	21.9	14	50.5	15	42	35	83	2	43	11	83
Yun Feng et al.	peer-reviewed	Case-Control	Severity	China	53	43.1	10.3	8	25.8	4	33	36	80	N/A	N/A	N/A	N/A
Zeng et al.	pre-print	Cross Sectional	All-cause Mortality & Severity	China	66.5	50.6	56	41.3	27.37	15	28	15	47	2	28	5	47
Zhang et al.	peer-reviewed	Cohort	All-cause Mortality	China	64	46	21.3	29.09	100	N/A	N/A	N/A	N/A	7	188	92	940
Zhichao Feng et al.	pre-print	Cohort	Severity	China	47	49.6	8	4	14.5	1	16	16	49	N/A	N/A	N/A	N/A
Zhong et al.	peer-reviewed	Retrospective Observational study	All-cause Mortality & Severity	UK	66.3	55.5	32.5	16.6	100	6	37	15	89	6	37	15	89

Table 2: New Castle Ottawa Scale

2A: Cohort studies

Study	Selection				Comparability	Outcome			Total (maximum = 9)
	Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of the exposure	Outcome status at start of study		Assessment of the outcome	Length of follow-up	Adequacy of follow-up	
Bae et al.	*	*	*	*	**	*	*	*	9
Baker et al.	*	*	*	*	-	*	*	*	7
Baneerje et al.	*	*	*	*	*	*	*	*	8
Beanet al.	*	*	*	*	-	*	*	*	7
Benelli et al.	*	*	*	*	-	*	*	*	7
Bravi et al.	*	*	*	*	*	*	*	*	8
Cariou et al.	*	*	*	*	*	*	*	*	8
Conversano et al.	*	*	*	*	**	*	*	*	9
De Spiegeleer et al.	*	*	*	*	**	*	*	*	9
Feng zhou et al.	*	*	*	*	-	*	-	*	6
Fosbol et al.	*	*	*	*	**	*	-	-	7
Golpe et al.	*	*	*	*	*	*	*	*	8
Guner et al.	*	*	*	*	*	*	*	*	8
Huang et al.	*	*	*	*	-	*	*	*	7
Jung et al.	*	*	*	*	**	*	*	*	9
Lee et al.	*	*	*	*	**	*	*	*	9

Mehta et al.	*	*	*	*	-	*	*	*	7
Otero et al.	*	*	*	*	*	*	*	*	8
Rentsch et al.	*	*	*	*	**	*	*	*	9
Rhee et al.	*	*	*	*	**	*	*	*	9
Rossi et al.	*	*	*	*	*	*	*	*	8
Yan et al.	*	*	*	*	*	*	*	*	8
Yang et al.	*	*	*	*	-	*	*	*	7
Yuchen et al.	*	*	*	*	-	*	*	*	7
Zhang et al.	*	*	*	*	**	*	*	*	9
Zhichao Feng et al.	*	*	*	*	*	*	*	*	8
Zhou et al.	*	*	*	*	*	*	*	*	8
Covino et al.	*	*	*	*	*	*	*	*	8
Chaudri et al.	*	*	*	*	*	*	*	*	8
Hakeam et al.	*	*	*	*	**	*	*	*	9
Zhong et al.	*	*	*	*	*	*	*	*	8
Lim et al.	*	*	*	*	*	*	*	*	8
Cetinkal et al.	*	*	*	*	**	*	*	*	9
Lafaurie et al.	*	*	*	*	**	*	*	*	9
Alexandre et al.	*	*	*	*	*	*	*	*	8
W Lam et al.	*	*	*	*	*	*	*	*	8
Soleimani et al.	*	*	*	*	-	*	*	*	7
Genet et al.	*	*	*	*	-	*	*	*	7
Hwan Kim et al.	*	*	*	*	**	*	*	*	9
Rodilla et al.	*	*	*	*	-	*	-	*	6
Oussalah et al.	*	*	*	*	*	*	*	*	8
Anzola et al.	*	*	*	*	**	*	*	*	9
Desai et al.	*	*	*	*	*	*	*	*	8
Xiulan et al.	*	*	*	*	-	*	*	*	7
Braude et al.	*	*	*	*	*	*	*	*	8
Rosenthal et al.	*	*	*	*	*	*	*	*	8
Huh et al.	*	*	*	*	**	*	*	*	9
Lee et al.	*	*	*	*	**	*	*	*	9

2B: Case control studies

Study	Selection				Comparability			Total (maximum = 10)
	Representativeness	Sample size	Non-respondents	Ascertainment of the exposure		Assessment of the outcome	Statistical test	
Ashraf, 2020	*	-	*	*	-	**	-	5
Chen, 2020	*	-	*	*	-	**	-	5
choi,2020	*	*	*	*	*	**	*	8
Felice, 2020	*	-	*	*	-	**	-	5
Guo, 2020	*	-	*	*	-	**	-	5
Ip, 2020	*	*	*	*	-	**	-	6
Jurado, 2020	*	*	*	*	-	**	-	6
Li, 2020	*	*	*	*	-	**	-	6
Liu, 2020	*	-	*	*	*	**	*	7
Mancia, 2020	*	*	*	*	-	**	-	6
Meng, 2020	*	-	*	*	-	**	-	5
Peng, 2020	*	-	*	*	-	**	-	5
Reynolds, 2020	*	*	*	*	**	**	*	9
Richardson, 2020	*	*	*	*	-	**	-	6
Tan, 2020	*	*	*	*	-	**	-	6
Wang, 2020	*	-	*	*	-	**	-	5
Yun Feng, 2020	*	-	*	*	-	**	-	5
Zeng, 2020	*	-	*	*	-	**	-	5
Bauer et al	*	*	*	*	**	**	*	9
Potts et al	*	-	*	*	*	**	*	7